This action follows a consumer report of fungal contamination in a sealed single-use vial. While no adverse events have been ...

As 2024 comes to a close, we here at Ophthalmology Times and the greater Eye Care Network would like to thank you–the reader.

The NYU Grossman School of Medicine launches a Journal Club series with Ophthalmology Times, featuring expert faculty ...

Deepinder Dhaliwal, MD, LAc, discusses longterm outcomes of Descemet Stripping Only (DSO) for Fuchs dystrophy at NYU's ...

A Helsinki University Hospital study found diabetes, glycemic control, or insulin therapy did not significantly affect ...

Alon Kahana, MD, PhD, discusses the role of interleukin-6 in thyroid eye disease and the potential of tourmaline Bio's IL-6 ...

Electrical stimulation therapy is being explored as a potential treatment to enhance neuroplasticity and improve visual ...

Deepinder Dhaliwal, MD, LAc, explores advancements in managing Fuchs endothelial corneal dystrophy, highlighting Descemet ...

Glaukos submitted an NDA for Epioxa, a novel corneal cross-linking therapy for keratoconus, to the US FDA. Epioxa's Phase 3 ...

Investigators conducted a retrospective clinical audit to determine why patients do not adhere to the guidelines among about 9,000 patients in a practice.

At the FLORetina Conference in Florence, Italy, John W. Kitchens, of Retina Associates of Kentucky, highlighted strategies to enhance efficiency in retina practices, addressing challenges like staff ...

CU06 showed dose-dependent improvements in visual acuity and anatomical markers in DME patients, with the 300 mg group achieving a 5.8-letter improvement. The trial confirmed CU06's safety, with no ...